Global Biosimilars Treatment Market 2034 - Key Facts

Global Biosimilars Treatment Market 2034 – Key Market Insights
Key Market Question	Answer
What is the market size in 2025?	$30,600 Million
What is the projected market size by 2035?	$65,900 Million
What is the market CAGR from 2025 to 2035?	8.0%
Which region dominates the market?	Europe (38%)
Which product/service type dominates the market?	Monoclonal Antibodies (37%)
Which application leads the market?	Oncology (42%)
Who are the major buyers?	Hospital Pharmacies (43%), Retail Pharmacies (29%)
What are the key market growth drivers?	Patent expirations of major biologic drugs have created significant opportunities for biosimilar manufacturers; Escalating demand for cost-effective treatments in chronic diseases such as cancer and diabetes is driving biosimilar uptake
What are the major market challenges?	Market acceptance barriers among clinicians and patients remain; Complex and evolving regulatory requirements across geographies increase development timelines and costs
What is the forecast period?	2026–2035
Who are the key market players?	Pfizer Inc., Novartis AG, Amgen Inc., Biocon Limited, Celltrion Healthcare, Samsung Bioepis, Mylan N.V., Teva Pharmaceutical Industries Ltd., Eli Lilly and Company, Merck & Co., Inc., Sandoz International GmbH, Hospira, Inc., Dr. Reddy's Laboratories, Boehringer Ingelheim, Biogen Inc.